Chugai Releases New Actemra Data, Rides Wave To Submit U.S. FDA Response In Third Quarter
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical, the Japanese division of Roche, June 10 released new data on rheumatoid arthritis drug Actemra (tociluzumab), which showed that up to 56 percent of patients with active RA treated with Actemra for more than two years achieved disease remission. Presented at the European League Against Rheumatism annual congress, the remission data provides Roche and Chugai refreshed vigor on its push for still-pending U.S. approval for tociluzumab